01—Abstract
Summary
Summary of the 8-K filed February 7, 2024. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported fourth-quarter and full-year 2023 results on February 7, 2024, with INGREZZA (valbenazine) driving growth.
Fourth-quarter total revenues were $515.2 milliona, and full-year total revenues were $1,887.1 million, compared with $1,488.7 million in 2022. INGREZZA net product sales were $500 million in the fourth quarter, up 25% year over year, and $1.84 billion for the full year, up 29%. Full-year GAAP net income was $249.7 million, or $2.47 per diluted share, versus $154.5 million, or $1.56 per diluted share, in 2022.
Full-year non-GAAP net income was $390.0 millionb, or $3.86 per diluted share. Cash, cash equivalents and marketable securities totaled $1,719.1 million at December 31, 2023. For 2024, the company guided to INGREZZA net product sales of $2.1 billion to $2.2 billion, GAAP R&D expense of $645 million to $675 million, and GAAP SG&A expense of $930 million to $950 million.
The guidance also states that SG&A reflects pre-launch commercial activities for crinecerfont. The company expects to submit a New Drug Application for crinecerfont to the FDA in the second quarter of 2024, following positive Phase 3 results in congenital adrenal hyperplasia. Crinecerfont received Breakthrough Therapy designation in December 2023.
A PDUFA date of April 30, 2024 is listed for the sprinkle formulation of valbenazine. Recent developments include the resolution of all patent litigation against companies that filed ANDAs for generic versions of INGREZZA.
Those companies may sell generic versions beginning March 2038, or earlier under certain circumstances. The filing also lists a series of 2024 pipeline milestones, including Phase 2 data readouts for several programs in the first and second halves of 2024.
02—Key points
Key Highlights
- Fourth-quarter 2023 total revenues were $515.2 million, versus $412.0 million in the fourth quarter of 2022; full-year total revenues were $1,887.1 million, versus $1,488.7 million.
- INGREZZA net product sales were $500 million in the fourth quarter (up 25% year over year) and $1.84 billion for full-year 2023 (up 29%).
- Full-year 2023 GAAP diluted EPS was $2.47, up from $1.56 in 2022; non-GAAP diluted EPS was $3.86, up from $3.47.
- 2024 INGREZZA net product sales guidance is $2.1 billion to $2.2 billion.
- Crinecerfont NDA submission to the FDA is expected in Q2 2024 for congenital adrenal hyperplasia in adults and pediatrics, after Breakthrough Therapy designation in December 2023.
- All patent litigation against ANDA filers for generic INGREZZA has been resolved; generic versions may be sold beginning March 2038, or earlier under certain circumstances.
- Cash, cash equivalents and marketable securities were $1,719.1 million at December 31, 2023, up from $1,288.7 million a year earlier.
03—Questions
Frequently Asked Questions
How did INGREZZA perform in 2023?
INGREZZA net product sales were $500 million in the fourth quarter of 2023, up 25% from the fourth quarter of 2022, and $1.84 billion for the full year, up 29%. The company attributed fourth-quarter growth to strong underlying patient demand, partly offset by seasonal gross-to-net dynamics.
What is the company's 2024 financial guidance?
The company guided to 2024 INGREZZA net product sales of $2.1 billion to $2.2 billion, GAAP R&D expense of $645 million to $675 million (non-GAAP $570 million to $600 million), and GAAP SG&A expense of $930 million to $950 million (non-GAAP $830 million to $850 million).
What are the key near-term regulatory and clinical catalysts?
The filing lists a PDUFA date of April 30, 2024 for the sprinkle formulation of valbenazine, a planned crinecerfont NDA submission in Q2 2024, and top-line Phase 2 data for several programs, including NBI-1065845 and Efmody, in the first half of 2024. Additional Phase 2 readouts for NBI-1117568, luvadaxistat and other programs are expected in the second half of 2024.
Are there risks to INGREZZA's long-term exclusivity?
The company stated that all patent litigation against ANDA filers seeking to market generic INGREZZA has been resolved. Those companies have the right to sell generic versions beginning March 2038, or earlier under certain circumstances.
04—Continue